Monthly Archives: November 2026

Synthesys Announces Collaboration with WisdomTree Following Registration of Three Tokenized Funds in Singapore

Synthesys Network will enable regulated intermediaries to access WisdomTree’s tokenized fund portfolio, starting with three funds spanning money markets, U.S. large-cap equities and technology strategies, following approval for distribution in Singapore.

SINGAPORE and NEW YORK, Nov. 17, 2026 — Synthesys, the financial market infrastructure company for tokenized capital markets, today announced a collaboration with WisdomTree (NYSE: WT), a global financial innovator, making WisdomTree’s tokenized funds accessible through regulated channels integrated into Synthesys Network.

Under the collaboration, the funds become accessible to regulated distribution partners connected through Synthesys Network a connective infrastructure layer enabling regulated distribution to over 80+ distribution channels globally. The first of these partners is Pinetree Securities, who will promote the WisdomTree tokenized funds to certain eligible institutional clients in Singapore that qualify under applicable laws, with further distribution partners to follow. 

The funds include the WisdomTree Money Market Digital Fund (WTGXX), WisdomTree 500 Digital Fund (SPXUX) and WisdomTree Technology and Innovation 100 Digital Fund (TECHX). WisdomTree has registered the funds in Singapore as restricted schemes, making them available to a wider range of eligible investors. Together, they provide eligible investors with access to USD cash management, U.S. large-cap equities and technology-focused exposure through tokenized, regulated investment vehicles.

Most tokenized funds still operate largely in silos. Each bank, fintech, brokerage or platform that wants to build on them must integrate with each manager separately, chain by chain and jurisdiction by jurisdiction, so even the best products reach only a fraction of their addressable market. Synthesys Network enables the connectivity and operational layer linking regulated distribution channels, spanning banks, payment service providers, fintechs and financial institutions across jurisdictions, to institutional-grade tokenized products through a single integration.

More than 80 regulated channels connected to Synthesys Network will be able to access the funds without building and maintaining a separate bilateral integration with WisdomTree, subject to each channel’s regulatory permissions and investor eligibility requirements, including completion of onboarding and investor due diligence.

“WisdomTree is a pioneer in the tokenized fund industry, with one of the largest tokenized portfolios spanning across different strategies. We’re excited to support their expansion with Synthesys Network, bringing these funds to more regulated distribution channels globally. When distribution stops being the bottleneck, the best products win, and investors get access that no longer depends on where they happen to bank.”

— Darien Poh, CEO, Synthesys

WisdomTree brings significant experience and scale to the Synthesys Network. The global asset manager offers 15 SEC-registered tokenized funds spanning money markets, equities, fixed income, asset allocation and alternatives across eight public blockchains. Its tokenized fund assets surpassed US$1.2 billion in September 2026, up from approximately US$770 million at the start of the year.

“Onchain finance is global by nature, and Singapore is an important market for its next stage of growth. Working with Synthesys gives us a practical way to bring WisdomTree’s tokenized funds to more eligible investors through the regulated channels they already use. If we continue to make regulated products easier to access and use across markets, then adoption will only continue to follow.”

— Vinh Tran, Associate Director of Business Development for WisdomTree Onchain

Availability through each channel remains subject to that channel’s regulatory permissions and investor eligibility. Access to products via Synthesys Network is available exclusively to regulated intermediaries and, through them, to eligible investors under applicable law.

###

About Synthesys and Pinetree

Synthesys is a financial market infrastructure company for tokenized funds and securities. Its flagship product, Synthesys Network, is an issuer-agnostic connectivity layer that gives regulated distribution channels such as banks, payment providers, fintechs and brokerages access to institutional-grade tokenized products through a single integration, with compliance and investor eligibility enforced at the network layer. Network today carries tokenized funds, offering yields in over ten currencies to over 80+ distribution channels globally. Alongside Network, Synthesys’ product suite enables traditional financial institutions to seamlessly build into the tokenized economy, including Synthesys Mint and Zodiac.

Learn more at synthesys.co. 

The foregoing activities with respect to the WisdomTree tokenized funds are facilitated via Pinetree Securities Pte. Ltd., the holder of a Capital Markets Services License and regulated by the Monetary Authority of Singapore to conduct the regulated activities, including dealing in capital markets products that are securities or collective investment schemes. Pinetree’s core business is to support its clients in any investment process, be it through the discovery and sharing of potential investment opportunities or through the identification and introduction of potential investors, leveraging its expertise and presence in the Singapore and South-East Asia markets.

Disclaimer: This communication is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any security or fund interest in any jurisdiction. Synthesys does not offer, sell or distribute securities. Products accessible via Synthesys Network are made available by regulated intermediaries, such as Pinetree, acting within their own regulatory permissions, and availability is subject to investor eligibility and jurisdiction.

About WisdomTree

WisdomTree is a modern global asset manager with capabilities across public markets, private markets, tokenization and onchain finance. We offer a diverse suite of exchange-traded products, models and solutions, private market investments and blockchain-enabled products and services, helping investors shape their financial future and financial professionals grow their businesses. Through WisdomTree Onchain™, we combine tokenized investment products, infrastructure and distribution capabilities into an integrated financial services platform serving retail and institutional investors.

WisdomTree currently has approximately US$172.3 billion in assets under management globally, inclusive of assets managed by Ceres Partners, LLC as of the last reportable period.

For more information about WisdomTree Onchain, visit: https://www.wisdomtree.com/onchain

Please visit us on X at @WisdomTreeOnchn.

WisdomTree® is the marketing name for WisdomTree, Inc. (NYSE: WT) and its subsidiaries worldwide. 

WisdomTree Digital Management, Inc., serves as the investment adviser to the WisdomTree Money Market Digital Fund (WTGXX), WisdomTree 500 Digital Fund (SPXUX) and WisdomTree Technology and Innovation 100 Digital Fund (TECHX) (the “Funds”), which are series of WisdomTree Digital Trust. WisdomTree Digital Management, Inc. and WisdomTree Digital Trust are registered with the U.S. Securities and Exchange Commission.  WisdomTree Digital Management has also registered the Funds as restricted schemes with the Monetary Authority of Singapore.

Investors should carefully consider the investment objectives, risks, charges and expenses of the Funds before investing, which may be obtained via Pinetree. There are risks involved with investing, including the possible loss of principal. Past performance does not guarantee future results.

You could lose money by investing in a Fund, including WTGXX. Although WTGXX  seeks to preserve the value of your investment at $1.00 per share, it cannot guarantee it will do so. An investment in the WTGXX is not a bank account and is not insured or guaranteed by the Federal Deposit Insurance Corporation or any other government agency. The Fund’s adviser is not required to reimburse the Fund for losses, and you should not expect that the adviser will provide financial support to the Fund at any time, including during periods of market stress.

Potential products and services, as well as applicable launch timing and associated fees, are in development, may change or may never become available, including due to regulatory considerations. Any information provided and/or plans associated herewith are subject to change without notice, and WisdomTree is under no obligation to provide additional information.

Media Contacts

Synthesys 
Media
Equitize Pte Ltd
[email protected]

WisdomTree
Media Relations
WisdomTree, Inc.
Jessica Zaloom
+1.917.267.3735
[email protected]

Investor Relations
WisdomTree, Inc.
Jeremy Campbell
+1.917.267.3859
[email protected]

SOURCE Synthesys

CPP Investments and Ontario Teachers’ to join Nordic Capital as owners of Cary Group to support its continued international expansion and long-term development

  • The new joint ownership will aim to accelerate growth through strategic acquisitions, operational excellence and digitalisation
  • The transaction builds on Cary Group’s significant transformation and international growth under Nordic Capital’s ownership since 2018

STOCKHOLM, Nov. 17, 2026 — Canada Pension Plan Investment Board (“CPP Investments”), Ontario Teachers’ Pension Plan Board (“Ontario Teachers'”), and Nordic Capital today announced an agreement to form a new consortium in Cary Group (“the Group”), a leading European provider of vehicle glass repair and replacement services, to support its next phase of growth. CPP Investments and Ontario Teachers’ will invest alongside Nordic Capital, which will make a new investment in Cary Group following the exit of its current holding. Each investor will hold an approximately equal ownership of the business. CVC Capital Partners XIII, which has been a co-owner since 2022, will fully exit its shareholding following a successful partnership.

The transaction marks an important new chapter for Cary Group following several years of significant growth and international expansion. Nordic Capital, CPP Investments and Ontario Teachers’ will combine their sector expertise, operational capabilities and international networks to drive Cary Group’s next phase of growth. Working closely with management, the consortium will focus on strengthening Cary Group’s position in existing markets, pursuing further international expansion through organic growth and strategic acquisitions, and advancing operational excellence and digitalisation.

Headquartered in Stockholm, Cary Group provides vehicle glass repair and replacement services, alongside a complementary offering in auto body repair. Today, it operates across 13 European countries, with approximately 1,800 workshops and 4,500 employees. The Group generated net revenue of SEK 9 billion (EUR 820 million), LTM October 2026,  and handled approximately 1.4 million vehicle glass jobs, reflecting the scale of its operations and its established position as a partner to insurers and motorists across Europe.

“Cary Group has achieved remarkable progress during Nordic Capital’s ownership since 2018, growing from a Swedish business with just over 100 workshops to a leading European platform with approximately 1,800 workshops across 13 countries through a combination of organic growth and strategic acquisitions. We would like to thank CVC for its partnership and contributions during the last four years. The decision to reinvest reflects a strong conviction in the Group’s potential, and Nordic Capital looks forward to building on this success with this new joint ownership,” said Joakim Andreasson, Partner and Co-Head of Services & Industrial Tech, Nordic Capital Advisors.

“Cary Group has established a leading position in Europe with a resilient business model and a strong track record of organic growth and strategic acquisitions. We see significant opportunity to continue building on this momentum across Europe and look forward to working alongside Nordic Capital, Ontario Teachers’ and the management team as the company enters its next phase of growth. The investment reflects CPP Investments’ strategy of investing in high-quality businesses with strong market positions that have the potential to deliver attractive long-term, risk-adjusted returns for the CPP Fund,” said Sam Blaichman, Managing Director and Head of Direct Private Equity at CPP Investments.

“This investment is exactly what we look for: a leading company, a high-quality team, and a sector with structural tailwinds. Cary Group’s proven model and challenger position give it a clear runway for growth across Europe, and we’re glad to be doing this alongside partners we know well in Nordic Capital and CPP Investments,” said Inaki Echave, Head of EMEA Private Capital at Ontario Teachers’. 

“Over the past few years, we have built a leading European business by consolidating a fragmented market through strategic acquisitions. At the same time, we have achieved strong organic growth by working closely with our customers and investing in operational improvements. We still see great opportunities ahead, and with this new ownership group, we are well positioned to accelerate our expansion in Europe and internationally, and to further strengthen our customer offering,” said Anders Jensen, CEO of Cary Group.

The ownership will be a consortium between Nordic Capital, CPP Investments and Ontario Teachers’, each holding an approximately equal co-control position. Nordic Capital will realise its existing investment in Cary Group and make a new investment alongside CPP Investments and Ontario Teachers’, reflecting its continued conviction in the company’s long-term growth prospects. Ontario Teachers and CPP Investments are expected to invest EUR 545 million (CAD 859 million) and EUR 500 million (CAD 790 million) respectively.

The transaction is subject to customary closing conditions and regulatory approvals and is expected to close in H1 2027.

Media contacts

Nordic Capital 
Katarina Janerud
Communications Manager, Nordic Capital Advisors
+46 8 440 50 50
[email protected] 

CPP Investments
Steve McCool
Public Affairs & Communications
+44 7780 224 245
[email protected]

Ontario Teachers’
Henrietta Dehn
Director of Communications, Ontario Teachers’
[email protected] 

Anelia Fikiina
Director, Kekst CNC
+44 7970 952 774
[email protected] 

Cary Group
Helene Gustafsson Director Corporate Communications
+46 708 68 40 50
[email protected] 

About Nordic Capital

Nordic Capital is a leading international private equity investor and subsector specialist dedicated to building stronger, more resilient businesses through transformative, long-term growth in partnership with management teams. With over 35 years of experience, Nordic Capital currently manages approximately EUR 39 billion in assets, investing in middle-market companies across Northern Europe and North America. Rooted in its Nordic heritage and values, it combines global reach with local presence through dedicated sector investment advisory teams, bringing deep expertise across its core sectors: Healthcare, Technology & Payments, Financial Services, and Services & Industrial Tech. Through active ownership, strong operational capabilities, a global network of experts and technology-enabled transformation, Nordic Capital helps companies scale, innovate and become sustainable leaders. For more information, visit www.nordiccapital.com or connect on LinkedIn.

“Nordic Capital” refers to, depending on the context, any, or all, Nordic Capital branded entities, vehicles, structures, and associated entities. The general partners and/or delegated portfolio managers of Nordic Capital’s entities and vehicles are advised by several non-discretionary sub-advisory entities, any or all of which are referred to as “Nordic Capital Advisors”.

About CPP Investments

Canada Pension Plan Investment Board (CPP Investments™) is a professional investment management organization that manages the Canada Pension Plan Fund in the best interest of the more than 22 million contributors and beneficiaries. In order to build diversified portfolios of assets, we make investments around the world in public equities, private equities, real estate, infrastructure, fixed income and alternative strategies including in partnership with funds. Headquartered in Toronto, with offices in Hong Kong, London, Mumbai, New York City, São Paulo and Sydney, CPP Investments is governed and managed independently of the Canada Pension Plan and at arm’s length from governments. At September 30, 2026, the Fund totalled C$866.2 billion. For more information, please visit www.cppinvestments.com or follow us on LinkedIn, Instagram or on X @CPPInvestments.

About Ontario Teachers’

Ontario Teachers’ Pension Plan Board (Ontario Teachers’) is a global investor with net assets of $303.2 billion as at June 30, 2026. Ontario Teachers’ is a fully funded defined benefit pension plan, and it invests in a broad array of asset classes to deliver retirement security for 346,000 working members and pensioners. For more information, visit otpp.com and follow us on LinkedIn.

About Cary Group

Cary Group is a leading European vehicle glass company, offering repair and replacement for private motorists, fleets, leasing companies and insurers. With around 1,800 workshops and 4,500 employees, we operate through several well-known brands across Europe. The company started in 1947 with Ryds Bilglas in Sweden. For more information, visit www.carygroup.com.

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

Boyuan Capital Completes Final Close of RMB 1.1 Billion Fund II, Focusing on Industrial AI and Globalization

SHANGHAI, Nov. 17, 2026 — Boyuan Capital has completed the final close of Fund II at approximately RMB 1.1 billion. As the Bosch Group’s only market-oriented investment platform, Boyuan Capital connects Chinese technological innovation with global industrial resources, helping promising businesses translate breakthroughs into scalable commercial applications.

Fund II has attracted a diverse group of limited partners, including national-level funds of funds, social security funds, industrial groups, financial institutions and local government-guided funds. Among them is STIHL, the German outdoor power equipment leader, whose participation further expands Boyuan’s international industrial ecosystem and cross-border collaboration opportunities.

From Industrial Investment to Co-Creation

Building on Fund I’s investments across automotive, new energy and intelligent manufacturing, Fund II concentrates on: deploying AI and embodied intelligence in industrial environments; creating new businesses through carve-outs, joint incubation and collaboration within Bosch’s industrial value chain; and supporting the global expansion of China’s advanced manufacturing companies.

This evolution reflects a shift from identifying opportunities within established value chains to actively shaping new businesses, connecting emerging technologies with industrial capabilities, customer relationships and global market access.

“Artificial intelligence is becoming a major force shaping the future of industry. However, technologies can only create lasting value when they are applied in industrial settings and solve real-world problems,” said Dr. Hongquan Jiang, Managing Partner and Chairman of Boyuan Capital. He highlighted Bosch’s industrial expertise, engineering capabilities and global network as key resources for identifying long-term opportunities.

Michael Zhu, Managing Partner and CEO of Boyuan Capital, emphasized the importance of moving beyond financial investment to actively building industrial ecosystems.

“We look further: Can its technology be deployed in real industrial environments? Can it deliver products and solutions at scale? And can the company bring China’s engineering and manufacturing capabilities to global markets?” he said.

Fund II has invested in seven companies. Representative investments include Bowintec, jointly incubated by Boyuan and Galbot to advance industrial embodied intelligence; Weifu Smart Sensing, jointly incubated by Weifu High-Tech and Bosch; robotics companies Linkhou Robotics and Inspire Robots; and X-Motors, which is exploring international opportunities starting in Indonesia.

Through OpenBosch and Bo-ignition, Boyuan connects portfolio companies with industrial use cases, engineering capabilities, customers and global networks, accelerating technology validation, commercialization and international expansion.

Boyuan will continue connecting technology, capital and industrial resources, transforming Chinese innovation into globally competitive industrial businesses.

Faex Health Brings AI-Powered Digestive Health Monitoring to HLTH 2026, Advancing the Conversation Around Preventive Healthcare

Co-Founder and CEO Landon Nattrass joins healthcare innovators in Las Vegas 
to explore how artificial intelligence, continuous monitoring and accessible technology can support earlier intervention and more connected care

LAS VEGAS, Nov. 16, 2026 — Faex Health, a digital health company that has developed AI-powered tools to help people better understand and track digestive wellness, is showcasing its groundbreaking app at HLTH 2026, taking place through Wed., Nov. 18, at The Venetian Expo in Las Vegas. Co-Founder and CEO Landon Nattrass is sharingFaex Health’s first-of-its-kind approach to continuous gastrointestinal health monitoring to healthcare leaders, investors and strategic partners, demonstrating how artificial intelligence can help bridge a longstanding gap in preventive care by transforming everyday digestive health information into actionable insights.

Centered on the theme “The Age of Intelligent Healthcare Is Here,” HLTH 2026 brings together healthcare executives, clinicians, investors, technology innovators and policymakers to explore the technologies and partnerships shaping the future of healthcare delivery. Faex Health’s participation underscores the growing potential for AI-powered tools to make preventive health monitoring more accessible, continuous, and scalable.

Through computer vision and machine learning, the Faex platform analyzes smartphone images of stool alongside user-reported symptoms and other contextual information. The technology organizes digestive health indicators, identifies patterns, and tracks changes over time, helping users better understand their digestive wellness while supporting opportunities for more informed conversations with healthcare professionals.

“Healthcare has made tremendous advances in diagnosing and treating diseases, but we still overlook valuable information that people generate every day,” said Landon Nattrass, co-founder and CEO of Faex Health. “Our vision is to make digestive health monitoring as accessible and routine as tracking sleep, activity, or heart rate. HLTH brings together the organizations and decision-makers who can help move innovations like ours from promising technology into meaningful global healthcare applications.”

Unlike conventional approaches that often depend on periodic appointments, laboratory testing, or the onset of symptoms, Faex Health has developed technology designed to support ongoing digestive wellness tracking through a familiar device: the smartphone. The platform allows users to capture images, document symptoms, and review changes in digestive health indicators over time. Its AI-assisted tools provide structured wellness information and educational guidance intended to complement, rather than replace, professional medical evaluation.

“Faex Health is automatic and easy to use for both professionals and patients. For professionals, it allows us to review data quickly, verify each participant’s status, and keep the study under orderly control,” said Cristian Araya Orostica, registered nurse at Hospital Dr. Sótero del Río in Santiago, Chile, where Faex Health is participating in FECAL-AI, an ongoing clinical validation study evaluating its AI-powered technology for colorectal cancer prescreening.

Faex Health is exploring applications for healthcare providers, health plans, employers, and population health organizations seeking scalable approaches to preventive health engagement. The company’s broader platform strategy includes tools for organizing longitudinal digestive health information into structured summaries that may support clinical review and institutional health programs, subject to applicable requirements and validation.

As healthcare organizations increasingly evaluate artificial intelligence for preventive care, Faex Health is emphasizing the importance of responsible deployment, clinical validation, and appropriate integration with established healthcare practices. The company is also investigating potential applications of its technology in gastrointestinal prescreening and clinical research, including approaches that may help identify individuals who could benefit from additional medical evaluation. These investigational applications remain distinct from the company’s current wellness-monitoring capabilities and are not intended to replace established colorectal cancer screening, diagnostic procedures or professional medical judgment.

“The real opportunity for AI in healthcare is not simply generating more information. It is helping make meaningful information available at the right time, in a way that patients and healthcare professionals can actually use,” Nattrass added. “For health plans, employers and healthcare systems, that means exploring technologies that can encourage engagement, improve visibility into health trends and potentially reduce barriers to preventive care.”

During HLTH 2026, Faex Health is presenting the cutting-edge technology to healthcare organizations, investors, and collaborators interested in the intersection of artificial intelligence, digestive health, longitudinal monitoring, and population health. The company sees opportunities for its technology to complement existing healthcare systems by supporting accessible, non-invasive participation, and providing structured information that may help individuals and care teams recognize changes in digestive wellness over time.

Nattrass is available for media interviews regarding responsible AI in healthcare, the evolution of preventive health monitoring, the challenges of building clinically credible digital health technologies and the role of strategic partnerships in bringing emerging innovations to market.

For more information or to schedule an interview, contact Shawna Seldon at [email protected] or +1 917-971-7852.

About Faex Health
Faex Health is a health technology company that has developed AI-powered solutions for preventive gastrointestinal health monitoring. Using computer vision, machine learning, and smartphone-based image analysis, the Faex platform helps users capture digestive health information, monitor patterns over time, and access personalized educational wellness insights. The company has developed solutions designed to support individuals, healthcare providers, health plans, employers, and population health organizations. Faex Health’s investigational clinical applications are intended to complement established medical screening and diagnostic pathways, not replace them. For more information, visit FaexHealth.com. Continue the conversation on LinkedIn, Facebook, TikTok, X, Reddit, and Instagram.

SOURCE Faex Health

Numa Triples ARR, Raises $45M Series C to Run the Entire Dealership

Led by Blue Cloud Ventures, the round brings total funding to $96 million, with more than 1,500 dealerships across the U.S. and Canada already running on Numa’s AI Operating System

SAN FRANCISCO, Nov. 16, 2026 — Numa, the AI Operating System for dealerships, today announced a $45 million Series C led by Blue Cloud Ventures, with participation from Threshold Ventures, Costanoa, Touring Capital, Gradient Ventures and Tokio Marine Future Fund. The round brings Numa’s total funding to $96 million. It caps a year in which Numa tripled in size, tripled its annual recurring revenue and became the AI system GM, FordDirect, BMW and Stellantis each put in front of their dealerships.

Numa has already won the hardest part of the dealership: the customer conversation. The system has handled more than 1 billion calls, texts and chats and booked more than 4 million appointments. Dealerships that run on Numa stay and grow with it. Net revenue retention has risen over the past year, and more dealerships are moving to longer agreements.

For decades, dealership software was built one task at a time. Each system kept its own record of what happened, and none of them acted on what the customer just said. The first wave of AI did not change that. It answered faster, then handed the work back to people to chase by hand.

Numa does not hand the work back. It knows not just who the customer is but what they need, and it acts on it: booking the visit, finding the right car, routing the call or flagging the customer about to leave.

“In two years, every general manager will have an AI COO,” said Tasso Roumeliotis, founder and CEO of Numa. “At more than 1,500 dealerships, they already do, and it is Numa. It knows every conversation in the store, sees what needs attention and runs the work that follows. That is not another dashboard or another point tool. It is an operating system. The DMS was built to record the dealership. It was never built to run it. Numa was, and this round puts more engineers to accelerate it.”

“What is unique about Numa is that the company understands the DNA and culture of a dealership and seamlessly AI-enables the workflow while empowering all constituents including the dealerships customers”, added Mir Arif, Managing Partner of Blue Cloud Ventures.  “Numa is not prescriptive but rather deeply understands the objectives of the BDC representative, the salesperson, the service technician, the parts specialist and the sales manager and significantly enhances their productivity.” 

“As an insurer, we view dealerships as a critical part of the ecosystem that supports customers throughout their vehicle ownership journey,” said Mitsutoshi Shizuru, Managing Executive Officer of Tokio Marine & Nichido Fire Insurance Co., Ltd, “Numa is using AI to make this important customer touchpoint faster, more efficient, and more seamless. We believe Numa’s technology has the potential to revolutionize the relationship between dealerships and their customers and help shape the next generation of mobility customer experiences in the U.S. and beyond.”

This year, Numa took its system across the whole store.

In the service lane, Numa already knows every conversation. In August, Numa acquired SocketTime to put the work behind those conversations into the same system, so what a customer tells the store and what the store does about it run in one place.

In sales, Numa for Sales, launched this month, as the first agent with Inventory Fluency. It knows every new and used vehicle on the lot down to the trim, features and miles, learns each buyer’s situation and gets them in the car that fits best, even when the one they called about has sold. Every qualified lead lands in the dealership’s CRM with the full conversation, so the salesperson who picks it up already knows the buyer.

On every line into the store, Operator, launched in September, is the first Precision Routing system for dealerships. It answers first, understands why each customer is calling and puts them in the right hands with that reason carried through. When the phone rings, everyone at the dealership knows the call is for them. Operator continues to climb above 95% with calls going to the right destination.

LiveCSI™ reads customer interactions as they happen and flags the ones putting satisfaction at risk while there is still time to fix them, instead of waiting for a survey to report what went wrong. In 90 days, it analyzed 50 million interactions.

Every dealership on Numa now has over 25+ natural voices to choose from, with regional accents, a new Spanish voice, sharper recognition of vehicle makes, models and VINs, and adjustable speaking speed. The voice on the line sounds like someone who works at the dealership. It comes at no added cost, with nothing for the store to set up.

Three of the largest automakers in North America have each chosen Numa. GM named Numa an iMR Approved Turnkey Vendor, and more than 240 GM dealerships run on Numa today. In those stores, reply times have dropped from 23 hours to 24 minutes, each store saves about $11,000 a month, and 86% of customers flagged as heat cases return for service within six months. FordDirect selected Numa as its strategic AI vendor, making Numa available to more than 3,000 Ford and Lincoln dealerships. Numa is also approved on Stellantis’ MarketCenter, opening access to more than 2,600 dealerships in the U.S. and 440 in Canada.

The operating system for the dealership is not on its way. It is already running.

To learn more, visit numa.com.

About Numa

Numa is the AI Operating System used by leading dealerships to modernize customer operations across voice, text, service, sales, fixed operations, and customer intelligence. Built for the complexity of dealership workflows, Numa combines AI agents, human-in-the-loop collaboration, operational intelligence, and LiveCSI™ to help dealerships respond faster, improve customer experience, increase productivity, identify store-level patterns, and run more intelligently.

Numa answers every call, books appointments, and protects CSI in real time, unifying every customer conversation across voice, text, and digital channels in one system.

Trusted by more than 1,500 dealerships across the U.S. and Canada, Numa is based in Silicon Valley and was founded by the team behind Location Labs. The company has raised $96 million from investors including Blue Cloud Ventures, Google, Threshold Ventures (founding investor of Tesla), Mitsui, Costanoa Ventures, Touring Capital, and Tokio Marine Future Fund. Inc. 5000 recognized Numa as the #443 fastest-growing company overall and the #1 fastest-growing dealership software company.

About Blue Cloud Ventures

Blue Cloud Ventures is a New York City-based venture growth firm that invests in leading AI software, AI infrastructure and cybersecurity companies. BCV has a track record of supporting visionary entrepreneurs from growth to exit, with a portfolio of over 55 category-defining software companies in the United States and Europe.

SOURCE Numa

Remedy Robotics Raises $62 Million Series B to Bring Life-Saving Cardiovascular Intervention to Patients Everywhere

Funding will support clinical trials, advancement toward FDA approval, and planned commercial deployment of the company’s AI-enabled endovascular robotic platform and software suite

SAN FRANCISCO, Nov. 16, 2026 — Remedy Robotics, Inc. (“Remedy”), a leading healthcare and physical AI company developing robotic systems for cardiovascular care and endovascular intervention, today announced it has raised $62 million in Series B funding to accelerate its mission of delivering flawless, immediate robotic care to all patients, regardless of location.

The funding will support several major milestones, including a planned pivotal clinical trial in partnership with the University of California and advancement toward FDA approval for neurovascular intervention. Remedy will also deploy prototype N1 Systems across its network of clinical partners, including through its strategic partnerships with SVIN Mission Thrombectomy and the Australian Stroke Alliance, while continuing to advance the system’s industry-leading AI capabilities and autonomous functions.

“Endovascular intervention is the gold standard treatment for stroke and many cardiovascular emergencies, yet access remains limited to a small number of hospitals. For these time-critical conditions, that’s devastating. Even when specialist intervention is available, treatment is often delayed, and complications are frustratingly common,” said Dr. David Bell, CEO and Co-founder of Remedy Robotics. “This funding will allow us to accelerate toward deployment of our N1 System so we can bring quality intervention to patients everywhere, regardless of geography.”

DCVC led the Series B, with participation from new investors including UC Investments (the University of California’s investment office), Skip Capital, and Hostplus (one of Australia’s largest pension funds). Existing investors Build Collective by Tony Fadell, Blackbird, Divergent Capital and KdT Ventures doubled down.

“Remedy Robotics represents a new generation of medical robotics and physical AI companies, focused not only on technical innovation, but on solving real-world challenges,” said James Hardiman, General Partner at DCVC. “We believe the company is uniquely positioned to redefine how life-saving intervention is delivered and are thrilled to support them as they advance toward broader clinical and commercial adoption.”

Remedy is finalizing development of the N1 System, an AI-enabled robotic platform and software suite that uses machine learning to analyze preoperative imaging, simulate cases in advance, provide real-time 3D-2D image registration and complete entire endovascular procedures robotically. Designed for on-site, remote, or autonomous operation, the system has the potential to dramatically expand access to and improve the quality of specialized neurovascular, coronary, and peripheral vascular care. Remedy now works with more than 100 hospitals worldwide and is among a small group of physical AI companies bringing robotics into real-world clinical use. In October 2025, Remedy announced that it had successfully completed the world’s first remote neurointerventional procedures using the N1 System.

“This funding will allow our world-leading hardware, software, and machine learning teams to progress the N1 system towards clinical trials and potential FDA approval, while also developing additional features including full autonomy,” said Jake Sganga, CTO and Co-founder of Remedy Robotics. “We are particularly excited to deepen our partnership with the University of California, having worked closely with their clinical experts since 2021, and as we prepare for our planned pivotal clinical trials to be held across the UC network.”

“Remedy is building the kind of company we look for at Blackbird: one with world-class technical talent, a massive global problem to solve, and the potential to create an entirely new category,” said Michael Tolo, Partner at Blackbird. “We believe Remedy is uniquely positioned to transform how endovascular care is delivered, and we are excited to support the company through its next phase of growth.”

Cardiovascular disease, including stroke and heart attack, is the leading cause of death globally—claiming nearly 20 million lives each year—about twice the toll of all cancers. Beyond the human cost, stroke alone carries an annual economic burden of approximately $891 billion worldwide through healthcare costs and lost productivity. Access to endovascular intervention, the most effective treatment for many cardiovascular conditions, remains severely limited because only highly specialized physicians at a small number of hospitals can perform it. Today, just 2.8 percent of eligible stroke patients worldwide have access to endovascular treatment, leaving millions each year with otherwise preventable disability. Because cardiovascular emergencies are so time-critical, patient outcomes vary sharply based on proximity to specialized care, even in countries with well-developed specialist networks, such as the United States. Remedy’s technology directly addresses this access gap, delivering expert care for stroke, severe heart attacks, hemorrhagic conditions, and other time-critical cardiovascular emergencies to patients wherever they are.

Remedy aims to elevate the standard of care across the cardiovascular continuum, from diagnosis to discharge and surveillance, with the goal of making flawless, immediate cardiovascular care available to patients everywhere, from San Francisco to rural areas of Arkansas where timely care is out of reach, or to Lagos, Nigeria, where intervention is almost entirely unavailable.

The N1 System is under development and is not currently available for sale or clinical use in any jurisdiction.

About Remedy Robotics
Remedy Robotics is a leading healthcare and physical AI company developing AI-enabled endovascular robotic systems and software for on-premise, remote, and autonomous intervention. Its proprietary N1 System combines robotics, AI, and advanced computer vision to raise the standard of care across the cardiovascular continuum—from diagnosis and intervention to discharge and surveillance—bringing expert-level treatment within reach of patients wherever they are. Remedy’s clinical and research work has been published in leading peer-reviewed journals, including Interventional Neuroradiology and the American Journal of Neuroradiology, and the company holds 48 patents covering its platform, including foundational patents in machine learning applied to surgical robotics. Headquartered in San Francisco, Remedy is backed by DCVC, Blackbird, UC Investments (the University of California’s investment office), and Tony Fadell’s Build Collective, among others, and partners with clinicians at leading medical institutions across the U.S. and worldwide. Remedy is also the exclusive robotic partner of SVIN Mission Thrombectomy, a global initiative dedicated to expanding access to stroke treatment worldwide. Learn more at www.remedyrobotics.com.

SOURCE Remedy Robotics, Inc.

Accountable Launches to Give Power to American Taxpayers

Co-founded by Acorns CEO Noah Kerner and Jeff Cruttenden, Accountable raises $20 million to help Americans file their taxes, follow their money, and ultimately decide how it is spent.

NEW YORK, Nov. 16, 2026 — Accountable, a new consumer tax and civic company, launched its waitlist today with the belief that taxpayers should be treated like investors in the country they fund. Investors expect transparency into how their money is put to work, accountability for how it is managed, and a voice in the decisions that shape where it goes. Taxpayers deserve the same.

Every year, Americans file more than 160 million federal income tax returns, while individuals— not corporations—account for roughly 85% of federal tax revenue. The average taxpayer spends about 12 hours preparing and completing a return, only to be left with a larger question once it’s filed: what did their money actually pay for?

Accountable’s first product, a tax filing platform designed around the needs of the taxpayer, will launch in January 2027 ahead of tax season. With a filer’s permission, Accountable retrieves available tax information and documents, prefills their return, and guides them through reviewing and submitting for one flat price of $76, with filing free for anyone experiencing financial hardship. Accountable customers will also receive a personalized taxpayer receipt showing an estimated breakdown of what their taxes fund across federal, state, and local government spending.

“Cumulatively, taxes are the largest check most of us will ever write, and it’s ridiculous that we don’t even get a receipt,” said Noah Kerner, co-founder of Accountable. “Taxpayers deserve a better experience: smart, fast and fair filing, transparency into what we’re paying for, and power over where our money goes. After all, it’s our money, we fund this country, and we should feel like shareholders in it.”

The filing platform is the first step in Accountable’s broader vision: help Americans file their taxes, follow their money and, over time, have a greater voice in how it is spent. Accountable is starting with filing because it is the most direct financial interaction most Americans have with government. Each year, Americans are asked to account for every dollar they earn. Accountability should go both ways.

For Kerner, Accountable is a continuation of a career spent giving everyday people more access and agency in complex financial systems. At Acorns, Kerner has helped over 15 million everyday Americans save & invest over $30 billion. At Say, he gave individual investors a voice in the companies they own. At Accountable, he wants to give taxpayers the same voice in the country they fund. The full team behind Accountable comes with a wealth of experience across tax, civic, investing, health, and consumer technology sectors.

“We backed Accountable because we believe the taxpayer is one of the biggest consumer categories still waiting to be reinvented,” said Lauren Kolodny, Founding Partner at Acrew Capital. “Noah has spent his career earning the trust of everyday Americans. With Accountable, he’s bringing that same consumer-first mindset to one of the most important financial relationships in their lives.”

“Americans have more tools than ever to understand where their money goes, except when it goes to the government,” said Brent Murri, Partner at M13. “At M13, we look for founders who transform complex, entrenched systems into experiences that give people greater control. Accountable has the potential to fundamentally change the relationship between Americans and the government they fund.”

Accountable has raised $20 million in total funding, including a seed round co-led by Acrew Capital and M13, with participation from Greycroft, Torch Capital, Treasury, 645 Ventures, Eniac Ventures, Lerer Hippeau, Tusk Ventures, and angel investors like Josh Wolfe, founder of Lux Capital, and Zach Perret, co-founder of Plaid. The capital will support the buildout of Accountable’s filing platform and team ahead of its January launch. Kerner will continue to serve as CEO of Acorns.

Americans can join the waitlist beginning today at AccountableUSA.com.

About Accountable
Accountable is a consumer tax and civic company on a mission to bring Americans closer to America. Its first product, a tax platform designed to give Power to the Taxpayer, launches for the 2027 tax season. Join the waitlist at AccountableUSA.com.

SOURCE Accountable

Windward Bio Lists on Nasdaq, Shares Up 68% on Debut

Pivotal bioVenture Partners China-backed biotech built under the NewCo model on China-licensed assets debuts on Nasdaq less than two years after founding

SHANGHAI, Nov. 16, 2026 — Windward Bio Group AG (Nasdaq: WWB), a clinical-stage biotechnology company and a portfolio company of Pivotal bioVenture Partners China, began trading on the Nasdaq Global Select Market on Nov. 13, 2026. The company priced its initial public offering at $17.00 per share and sold approximately 10.29 million ordinary shares, raising $225 million in gross proceeds, including a $50 million concurrent private placement from Sanofi. Windward closed its first day of trading with a market capitalization of approximately $1.69 billion.

Windward was founded in 2024 by serial entrepreneur Luca Santarelli, M.D., and his team, whose prior companies VectivBio and Therachon were both acquired. Since inception, the company has raised $365 million, including a $200 million Series A in January 2025 and a $165 million crossover financing in May 2026. Pivotal bioVenture Partners is among the investors that have backed Windward through every financing round since its earliest days, from formation to a Nasdaq listing in under two years.

Headquartered in Basel, Switzerland, Windward develops ultra-long-acting antibody medicines for serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis. Its lead program, WIN378, is an ultra-long-acting, fully human monoclonal antibody against thymic stromal lymphopoietin (TSLP) now advancing through POLARIS-1, a Phase 2/3 study in asthma, and SIRIUS, a Phase 2 study in COPD. Designed for twice-yearly dosing, versus the once-every-four-weeks regimen of currently approved agents, WIN378 could meaningfully ease the long-term treatment burden for patients with chronic airway disease. In September 2026, the company reported positive interim Phase 2 data supporting twice-yearly dosing of WIN378 in asthma. Windward’s pipeline also includes WIN027, a clinical-stage bispecific antibody targeting TSLP and IL-13 now in Phase 1 development.

The global rights (excluding Greater China and certain Asian markets) to both of Windward’s core programs were licensed from Chinese biopharmaceutical companies. WIN378 (HBM9378/SKB378) came out of a co-development program between Harbour BioMed and Kelun-Biotech, while WIN027 (QX027N) was licensed from Qyuns Therapeutics. Windward is the latest example of China-originated drug candidates reaching global capital markets through license-out deals.

Windward is a leading case of the NewCo model in the current wave of Chinese biotech going global: a global investment firm leads the spin-out and licensing of a Chinese company’s pipeline asset, sets up a new entity overseas, and arms it with international capital and an experienced operating team to run clinical development and commercialization worldwide — typically excluding Greater China. Pivotal bioVenture Partners China’s practice has been a consistent investor, participating in the $200 million Series A in January 2025, increasing its position in the $165 million crossover round in May 2026, and remaining a shareholder through the IPO. In less than two years, Windward has completed the full path from “China asset licensing” to “NewCo formation” to “global financing” to “IPO listing,” plugging China-originated innovation into the global value chain.

According to company disclosures, net proceeds from the offering will be used primarily for completing core clinical development of WIN378, including the Phase 2/3 and confirmatory asthma studies and the Phase 2 COPD study; advancing the global Phase 2b COPD trial and the Phase 2 atopic dermatitis trial of WIN027, the latter expected to begin enrollment in the first half of 2027; moving the bispecific program to Investigational New Drug (IND) readiness; and funding working capital and general corporate purposes. After the offering, the pipeline is expected to reach three key data milestones: top-line Phase 2 asthma data for WIN378 (POLARIS-1) in the first half of 2027, Phase 2 COPD data (SIRIUS) in the second half of 2027, and Phase 3 asthma data in the first half of 2029.

For Pivotal bioVenture Partners, Windward Bio is a prime example of the NewCo model at work — China-originated innovation matched with global capital and world-class execution. From the start, the firm saw WIN378 and WIN027 as potential best-in-class, ultra-long-acting biologics for serious respiratory and dermatologic diseases, and it has backed Luca Santarelli and his team through every financing round since formation. The Nasdaq listing in under two years — putting the value of assets originated by its Chinese partners Harbour BioMed, Kelun-Biotech and Qyuns Therapeutics on the global stage — is a milestone for Pivotal, which plans to keep supporting Windward through its next phase of growth.

About Windward Bio

Windward Bio is a clinical-stage biotechnology company with deep drug discovery, development and commercialization experience, focused on transforming the treatment of serious immunological diseases, including respiratory and dermatologic conditions. Its lead program, WIN378, is an ultra-long-acting anti-TSLP monoclonal antibody with best-in-class potential, now in Phase 2/3 clinical trials for asthma. The company’s pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLP×IL-13 bispecific antibody with broad therapeutic potential across inflammatory diseases, now in Phase 1. Windward is also building a long-acting bispecific antibody discovery pipeline focused on validated targets in respiratory and dermatologic diseases.

About Pivotal bioVenture Partners

Pivotal bioVenture Partners was founded by Hong Kong’s Nan Fung Group. Since launching its U.S. operations in 2017 and its China practice in 2018, Pivotal has built broad international reach and global resource-coordination capabilities. The firm seeks out innovative products and technologies worldwide, founding and investing in leading life-science companies in Greater China to meet growing medical needs in global markets — particularly China. Pivotal invests across biopharmaceuticals, medical devices and healthcare services. Its team of seasoned life-science investors and entrepreneurs brings deep industry experience in company creation and venture investment.

Contact:
Phone: +86-21-68503033
Email: [email protected]

SOURCE Pivotal bioVenture Partners China

Gemspring Capital Closes Fourth Buyout Fund at $3.5 Billion Hard Cap

WESTPORT, Conn., Nov. 16, 2026 — Gemspring Capital Management, LP (“Gemspring”), a middle-market private equity firm, today announced the formation of its fourth buyout fund, Gemspring Capital Fund IV, LP (“Fund IV”), at $3.5 billion. Fund IV was oversubscribed and reached its hard cap in less than three months, holding a single close on all institutional limited partner commitments.

“We are grateful for the strong support from both our existing and new limited partners,” said Bret Wiener, Founder and CEO of Gemspring. “The successful fundraise reflects the strength of our team, our differentiated investment approach, and our track record of building great businesses.”

Consistent with prior funds, the Gemspring team made a substantial capital commitment to Fund IV, making it the Fund’s largest single investor.

Gemspring also manages Gemspring Growth Solutions, a complementary non-control investment strategy that closed its second fund at $1.1 billion in 2025.

Sidley Austin LLP served as legal counsel to Gemspring in connection with Fund IV.

About Gemspring Capital

Gemspring Capital, a Westport, Connecticut-based private equity firm with approximately $9 billion of capital under management, provides flexible capital solutions to middle-market companies. Gemspring partners with talented management teams to accelerate growth, drive value creation, and build great businesses. Target companies have up to $2.0 billion in revenue and operate across the aerospace & defense, business services, consumer services, financial and insurance services, healthcare, industrial, software, and tech-enabled services sectors. For more information, visit www.gemspring.com.

Contact: Jack Tucker, [email protected]

SOURCE Gemspring Capital